Trial Profile

A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 20 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dostarlimab (Primary) ; Niraparib (Primary)
Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms MOONSTONE
Sponsors GSK; TESARO

25 Oct 2023 Primary endpoint of Objective Response Rate has not been met, as per results presented at Gynecologic Oncology.
25 Oct 2023 Interim Results(n=41)assessing Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer, presented at the Gynecologic Oncology
07 Jun 2022 Interim results (data cutoff 6 Oct 2021; n=41) assessing efficacy in patients without BRCA mutation, presented at the 58th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com